Extremely late drug-eluting stent thrombosis related to uncovered struts: the phantom menace.
نویسندگان
چکیده
clinical practice. Eur Heart J 2012;33:2782–2795. 5. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC. Use of aldosterone antagonists in heart failure. JAMA 2009;302: 1658–1665. 6. Rossignol P, Cleland JG, Bhandari S, Tala S, Gustafsson F, Fay R, Lamiral Z, Dobre D, Pitt B, Zannad F. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights fromthe EplerenonePost-AcuteMyocardial InfarctionHeart Failure Efficacy and Survival Study. Circulation 2012;125:271–279. 7. Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol 2012;350:266–272. 8. Fraccarollo D, Bauersachs J. Cardiomyocyte mineralocorticoid receptor function post myocardial infarction. Trends Cardiovasc Med 2011;21:42–47. 9. Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schütz G, Frantz S, Ertl G, Bauersachs J. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 2011;123:400–408. 10. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME, Jaffe IZ. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 2012;18:1429–1433. 11. Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 2012;350:310–317. 12. Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Pérez S, Heckroth H, Nitsche A, Ergüden JK, Gielen-Haertwig H, Schlemmer KH, Mittendorf J, Paulsen H, Platzek J, Kolkhof P. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 2012;7: 1385–1403. 13. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim S-Y, Zannad F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013;34:2453–2463. 14. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21.
منابع مشابه
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
BACKGROUND Late stent thrombosis (LST) after Cypher and Taxus drug-eluting stent placement has emerged as a major concern. Although the clinical predictors of LST have been reported, specific morphological and histological correlates of LST remain unknown. METHODS AND RESULTS From a registry totaling 81 human autopsies of drug-eluting stents, 46 (62 lesions) had a drug-eluting stent implanted...
متن کاملDrug-eluting stent malapposition and its relationship to drug-eluting stent thrombosis
Stent malapposition (whether acute and persistent, or late and acquired) is common, occurring in 10–20% of drug-eluting stent implantations in stable patients and 30–40% of ST-elevated myocardial infarction patients. Acute stent malapposition is not a predictor of early stent thrombosis. Conversely, late stent malapposition, especially the large late stent malapposition area, might be a cause o...
متن کاملMechanisms of late stent-related myocardial infarction: insights from optical coherence tomography
This article focuses on optical coherence tomography findings in patients with late major cardiovascular events like myocardial infarction and/or stent thrombosis, following drug-eluting stent and bare-metal stent implantation. Uncovered stent struts and malapposition seem to play a critical role in drug-eluting stent-related late events. Neointimal features similar to native atherosclerosis ar...
متن کاملMechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography.
BACKGROUND The pathomechanisms underlying very late stent thrombosis (VLST) after implantation of drug-eluting stents (DES) are incompletely understood. Using optical coherence tomography, we investigated potential causes of this adverse event. METHODS AND RESULTS Between August 2010 and December 2014, 64 patients were investigated at the time point of VLST as part of an international optical...
متن کاملPathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement
Several randomized and observational studies have reported steady increase in cumulative incidence of late and very late ST (LST/VLST) following first-generation drug-eluting stents (DES: sirolimus-(SES) and paclitaxel-(PES)) up to 5 years. Pathologic studies have identified uncovered struts as the primary substrate responsible for LST/VLST following DES, where delayed arterial healing is assoc...
متن کاملOptical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis
BACKGROUND Stent thrombosis (ST) is a serious complication following coronary stenting. Intravascular optical coherence tomography (OCT) may provide insights into mechanistic processes leading to ST. We performed a prospective, multicenter study to evaluate OCT findings in patients with ST. METHODS Consecutive patients presenting with ST were prospectively enrolled in a registry by using a ce...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- European heart journal
دوره 34 31 شماره
صفحات -
تاریخ انتشار 2013